Det anbefales, at patienter i behandling med nelarabin får intravenøs hydrering i henhold til normal medicinsk praksis for behandling af hyperurikæmi hos patienter med risiko for tumor- lysis- syndrom.
Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumour lysis syndrome.